Seng Chin Mah

Seng Chin Mah is Chief Executive Officer of the Canyon Pharmaceuticals Group AG and has over 30 years of experience in the Pharma and Biotech industry. Prior to Canyon, he was the Head of Development of the Integration Office during the integration of Chiron into Novartis and has previously held positions including Global Head of Clinical Safety and Epidemiology, and Head of Drug Regulatory Affairs Europe. He also had oversight responsibility for Clinical Quality Assurance. Dr. Mah was also a member of the Novartis Corporate Executive Group and a member of the board of directors for Novartis Europharm Ltd. During his tenure with Novartis and Ciba, he has driven transformational programs, managed large global organizations, and achieved significant business results such as the numerous global registrations of major products including Diovan. Dr. Mah has worked extensively on both development projects and marketed products. He has held numerous research and academia positions and is currently on the boards of several biotech companies. Dr. Mah is an award-winning CEO of biotech - The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). He subsequently affected an asset transaction of the product. He possesses deep knowledge in strategic decision-making within the Pharma and Biotech industry, late-stage clinical development & regulatory experience as well as people development skills.